AIDS Treatment News logo      

December 24, 2010

Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV

Aidsmap: "Bristol Myers-Squibb will pay up to $286 million for development rights to festinavir, a new once-daily nucleoside reverse transcriptase inhibitor that is active against viruses resistant to both tenofovir and abacavir, the company announced on December 20th.

"Festinavir is a derivative of d4T (stavudine), but its developers say it is far less toxic than that drug."